1月5日 - ** 制药商Incyte INCY.O股价盘前上涨2.3%，报103.73美元
** INCY称， (link)，其实验性组合疗法在一项测试血癌患者的晚期试验中达到了主要目标。
** 该试验测试了他法西他单抗、来那度胺和标准化疗的组合疗法，该疗法改善了新确诊的弥漫大B细胞淋巴瘤患者的无进展生存期。
** Incyte 计划在 2026 年上半年申请扩大批准范围
** 在过去 12 个月中，股价累计上涨 2.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.